Overview

The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients

Status:
Unknown status

Trial end date:
2013-06-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to research the safety and efficacy of Albis® for the prevention of aspirin-induced gastrointestinal ulcers in patients taking low-dose aspirin.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Treatments:

Aspirin

Criteria

Inclusion Criteria:

- Male or female, aged 20 to 80 years

- Subjects identified with at least one of the following diagnosis (Angina, Myocardial
Infarction(Old), Cerebrovascular Disease, Peripheral Vascular Disease, Diabetes,
Hypertension, Hypercholeseterolemia, Obesity) who are required to take a low dose of
Aspirin (100mg/day) for more than 12 weeks.

Exclusion Criteria:

- Females who are pregnant, nursing, or planning a pregnancy during the study period or
females of childbearing potential

- Peptic ulcer or Reflux oesophagitis

- hemostatic disorder or coagulation disorder

- Known allergy or hypersensitivity to the study medication